Tuesday, June 30, 2009, 11:36am EDT
Wyeth Pharmaceuticals, Catalyst collaborating on hemophilia drug
Philadelphia Business Journal
Collegeville, Pa.-based Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) said it will pay South San Francisco, Calif.-based Catalyst $21 million upfront. Total payments for research funding and milestones could exceed $500 million, the companies said.
Wyeth Research President Mikael Dolsten said the relationship is “an opportunity to expand Wyeth’s hemophilia franchise.”
Catalyst has a drug candidate, known as CB 813, for treatment and prevention of acute bleeding in hemophilia patients.